GLP-1 Drugs Unlock Surprising Health Benefits Beyond Weight Loss

Got story updates? Submit your updates here. ›

GLP-1-class weight-loss drugs are helping Americans shed significant weight and embrace more active lifestyles. But the story doesn't finish with a smaller waistline. Researchers are uncovering a cascade of benefits extending to vital organ systems, sparking a revolution in how we approach chronic disease.

Why it matters

One in eight Americans are now utilizing these medications, which gained prominence in the early 2020s. The emerging research highlights a powerful connection between these drugs and the reduction of harmful inflammation - a key driver in the development of several deadly conditions.

The details

GLP-1s can reduce hospitalizations and deaths in people with heart failure where the heart doesn't fill properly (HFpEF). Recent studies also demonstrate a reduction in the risk of heart attacks and strokes. Researchers have found GLP-1s can prevent further tissue damage following a heart attack and limit complications. GLP-1s can also reduce the risk of kidney disease worsening and even prevent kidney failure, by controlling blood sugar levels. Additionally, GLP-1s can reverse liver scarring caused by metabolic dysfunction-associated steatotic liver disease (MASH), a leading cause of liver transplants. Purdue University researchers found GLP-1 users may have a reduced risk of developing 14 types of cancer, including a 47% lower risk of ovarian cancer.

• In the early 2020s, GLP-1 medications gained prominence.
• In August, the U.S. Food and Drug Administration approved Wegovy for treating MASH in adults with excessive liver scar tissue.

What they’re saying

What’s next

Further research is crucial to fully understand the long-term effects and potential applications of GLP-1 drugs. As scientists continue to unravel the complexities of these medications, one can expect even more groundbreaking discoveries that reshape the future of chronic disease management.